MediMergent Launches Pilot Program Deploying Virtual Human Advocates to Facilitate Community-Based Clinical Research
Sandra Garrett, Ph.D., the CEO of MediMergent states: 'At a time when more research programs are being directed towards community-based medical practices, the number of clinical trial staff has been significantly reduced. Without additional resources, practices are turning away research opportunities. Our VHAs provide intelligent and interactive methods for monitoring and tracking outcomes while communicating and supporting patient compliance and retention. The VHAs fill a critical gap by off-loading select time-consuming activities, thereby freeing up the study personnel to focus on clinical events.'
About MediMergent: MediMergent, LLC, a Real-World Evidence Company, supports a suite of AI-driven digital applications for data collection, integration, and analytics deployed in pre- and post-approval research for drugs, biologics, and medical devices. With an emphasis on 'Voice of the Patient' data, including emotion detection, intent, attitudes, behaviors, cognition, and other biomarkers, MediMergent 's technologies can impact patients' Quality of Life, adherence, persistence, stress, anxiety, and other outcome measures. Under an extended public/private partnership with the FDA, MediMergent has commercialized three digital platforms including MediManager ™ for digital management of clinical trials, MediMentor ™ for enhanced patient engagement and education, and MediMetrics ™ a curated data base that integrates multiple sources of Real-World Data and proprietary analytics to generate Real-World Evidence.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
27 minutes ago
- Business Wire
Accord Announces Amendment to its Banking Facility
TORONTO--(BUSINESS WIRE)--Accord Financial Corp. (TSX – ACD) today announced it has amended its senior secured revolving credit facility (the 'Credit Facility'), extending the maturity date to December 15, 2025. This amendment follows two recent short-term extensions: the first announced on July 25, 2025, and the second on August 8, 2025, which extended the maturity date to August 15, 2025. Under the new terms, the total commitment will be reduced from $260 million to $200 million. The amendment also incorporates milestones tied to potential asset sales (with net proceeds to be used to repay bank indebtedness), increases the interest rate on drawn amounts by 1.00%, and updates certain financial covenants. 'While the amendment includes higher pricing and a reduced commitment, the extension provides time for the Company to continue to actively pursue a broad range of strategic initiatives to address the Company's maturing debt obligations (totalling $217.6 million as at June 30, 2025 and coming due by January 31, 2026) and maximize shareholder value,' said Mr. Hitzig. 'These include potential divestitures of portfolio assets or business units, as well as other financing alternatives. The Company continues to work closely with its financial advisors, but there is no assurance that these initiatives will yield a successful result. While we focus on these initiatives, profitable operating performance and growth will continue to be a challenge.' The Company does not plan to provide further updates on its strategic initiatives unless material developments emerge. A Material Change Report and the amended Credit Facility agreement will be filed on SEDAR+ at About Accord Financial Corp. Accord Financial is one of North America's most dynamic commercial finance companies providing fast, versatile financing solutions including asset-based lending, factoring, inventory finance, equipment finance (in Canada), trade finance and film/media finance. By leveraging our unique combination of deep experience and independent thinking, we craft winning financial solutions for small and medium-sized businesses, simply delivered, so our clients can thrive. For further information please visit or contact: Forward-Looking Statements This news release contains certain "forward-looking statements" and certain "forward-looking information" as defined under applicable Canadian securities laws. Forward-looking statements can generally be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "anticipate", "believe", "continue", "plans" or similar terminology. Forward-looking statements in this news release include, but are not limited to, statements, management's beliefs, expectations or intentions regarding the financial position of the Company and the ability of the Company to repay or refinance its outstanding debt obligations. Forward-looking statements are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements are subject to various risks and uncertainties including the Company's overall liquidity and capital resource position and its ability to repay its debt obligations when due and those risks identified in the Accord's periodic filings with Canadian securities regulators. If any or all of the Company's outstanding debt obligations are not renewed or replaced upon expiration of their terms, and if the Company is unsuccessful in its ability to generate additional capital from sales of portfolio assets and/or business units and additional alternative financing arrangements to repay same on terms acceptable to the Company, or at all, the Company may not be able to continue to finance its operations and operate as a going concern. See Accord's most recent annual information form and most recent management's discussion and analysis of results of operations and financial condition for a detailed discussion of the risk factors affecting Accord. Such forward-looking information represents management's best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.
Business Wire
an hour ago
- Business Wire
Elizabeth Walker Wadsworth, MD, MSCR, Joins Advanced ENT & Allergy, Bringing Expert ENT and Inspire® Sleep Apnea Care to Atlanta
ATLANTA--(BUSINESS WIRE)--Advanced ENT & Allergy is pleased to welcome Elizabeth Walker Wadsworth, MD, MSCR, a highly trained otolaryngologist from Atlanta's Buckhead community. Dr. Wadsworth provides comprehensive care for adults and children with conditions of the ear, nose, and throat, with special expertise in chronic sinusitis, hearing loss, and innovative treatments for sleep apnea, including the Inspire® implantable device. Dr. Wadsworth returning to Atlanta to treat the community she grew up in. Share Dr. Wadsworth earned her medical degree from Emory University School of Medicine and completed her residency in Otolaryngology–Head and Neck Surgery at the Medical University of South Carolina (MUSC), a top-ten residency program nationally. She is board-eligible in otolaryngology and is committed to delivering individualized, evidence-based care that improves breathing, hearing, and sleep health. 'As someone who grew up in Buckhead, it's a privilege to return home to care for patients in the city that shaped me,' said Dr. Wadsworth. 'Whether I'm helping a patient breathe easier, hear better, or finally sleep soundly, I strive to combine the best available treatments with genuine compassion and clear communication.' During her residency, Dr. Wadsworth gained extensive experience in advanced sinus surgery, ENT allergy management, pediatric and adult hearing loss, and the surgical implantation of the Inspire® upper airway stimulation system — an effective alternative for patients with obstructive sleep apnea who cannot tolerate CPAP therapy. Dr. Wadsworth is now accepting new patients at Advanced ENT & Allergy, located at 960 Johnson Ferry Rd NE, Suite 200, Atlanta, GA 30342. About Advanced ENT & Allergy Advanced ENT & Allergy is a leading provider of comprehensive ear, nose, and throat care in the Atlanta area. Our board-certified providers emphasize advanced treatment options, patient education, and individualized service in a welcoming, service-oriented environment.
Business Wire
an hour ago
- Business Wire
LifeX Term Income ETFs Announce the Closure and Liquidation of Two Exchange-Traded Funds
NEW YORK--(BUSINESS WIRE)--LifeX Term Income ETFs ('LifeX') has announced that it will close and liquidate two exchange-traded funds to simplify its fund lineup. LifeX will be liquidating the LifeX 2040 Term Income ETF and LifeX 2045 Term Income ETF (together, the 'Liquidating ETFs') (such transactions, the 'Liquidations'). The Liquidations are expected to take place on or about August 22, 2025 (the 'Liquidation Date'). August 20, 2025 is expected to be the last full day of trading for the Liquidating ETFs' shares. The Liquidating ETFs expect to operate pursuant to their stated investment strategies through the Liquidation Date. While the investment objective of each Liquidating ETF is to provide monthly distributions through the year in such Liquidating ETF's name, the Liquidating ETFs will instead seek to liquidate and distribute their remaining assets to shareholders promptly following the Liquidation Date. In each case, the liquidation proceeds are expected to be distributed promptly following the Liquidation Date in full redemption of each shareholder's shares of the Liquidating ETFs. For additional information about the liquidations, shareholders of the Liquidating ETFs may call 855-609-3680. About LifeX Term Income ETFs LifeX Term Income ETFs are designed to provide reliable monthly distributions consisting of income and principal through the end of a calendar year specified in the ETF's prospectus. To learn more, please visit Risk Disclosures Investing involves risk. Principal loss is possible. Investors should consider the investment objectives, risks, charges, and expenses carefully before investing. For a prospectus with this and other information about the fund, please visit or call 855-609-3680. Please read the prospectus carefully before investing. Distributed by Foreside Financial Services, LLC.
